Compass Therapeutics (CMPX) EBIT Margin (2024)
Compass Therapeutics' (CMPX) quarterly EBIT Margin came in at 1770.0% in Q2 2024.
Compass Therapeutics (CMPX) EBIT Margin (2024) Analysis & Trends
Compass Therapeutics has disclosed EBIT Margin across 1 years of filings, most recently posting 1770.0% for Q2 2024.
- EBIT Margin for Q2 2024 came in at 1770.0%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 7981.76% (down 149541.0% YoY), and the FY2024 annual result was 6661.76%, changed N/A from the prior year.
- EBIT Margin came in at 1770.0% for Q2 2024 at Compass Therapeutics.
- In the past five years, EBIT Margin ranged from a high of 1770.0% in Q2 2024 to a low of 1770.0% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Compass Therapeutics | 387.71 Mn | 193.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1,770.00% |